Stockscreener 앱 받기
82.74
0.50%
0.76
전일 마감가:
$83.50
열려 있는:
$84.32
하루 거래량:
1,627
Relative Volume:
0.01
시가총액:
$816.98M
수익:
-
순이익/손실:
$-14.23M
주가수익비율:
-42.66
EPS:
-1.9396
순현금흐름:
$-9.44M
1주 성능:
+12.58%
1개월 성능:
-5.88%
6개월 성능:
+26.84%
1년 성능:
+189.28%
1일 변동 폭
$83.47
$84.70
1주일 범위
$76.99
$86.56
52주 변동 폭
$23.18
$123.75
Bright Minds Biosciences Inc Stock (DRUG) Company Profile
Compare DRUG vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DRUG
Bright Minds Biosciences Inc
|
83.47 | 817.23M | 0 | -14.23M | -9.44M | -1.9396 |
VRTX
Vertex Pharmaceuticals Inc
|
437.29 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
639.93 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.14 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
299.40 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.27 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-13 | 개시 | Jefferies | Buy |
| 2025-09-08 | 개시 | BTIG Research | Buy |
| 2025-05-13 | 개시 | TD Cowen | Buy |
| 2025-05-07 | 개시 | Chardan Capital Markets | Buy |
| 2025-01-23 | 개시 | Piper Sandler | Overweight |
| 2025-01-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-01-10 | 개시 | H.C. Wainwright | Buy |
| 2024-11-26 | 개시 | Robert W. Baird | Outperform |
모두보기
Bright Minds Biosciences Inc 주식(DRUG)의 최신 뉴스
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline - AOL.com
B Group Discloses New Position in Bright Minds Biosciences - HarianBasis.co
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline - The Motley Fool
Bright Minds Biosciences Stock Jumps After $220 Piper Sandler Call—What DRUG Traders Are Watching - Bez Kabli
Piper Sandler raises Bright Minds stock price target on program progress - Investing.com UK
Piper Sandler Maintains Bright Minds Biosciences(DRUG.US) With Buy Rating, Raises Target Price to $220 - Moomoo
Piper Sandler raises Bright Minds stock price target on program progress By Investing.com - Investing.com South Africa
Bright Minds Biosciences Boosts Cash Reserves as R&D Losses Widen in Q2 2026 Filing - TipRanks
[6-K] BRIGHT MINDS BIOSCIENCES INC. Current Report (Foreign Issuer) | DRUG SEC FilingForm 6-K - Stock Titan
Vestal Point (DRUG) and Ryan Wilder report 492,319 shares, 5% stake - Stock Titan
Janus Henderson (DRUG) discloses 1.28M shares, 13.1% stake - Stock Titan
Janus Henderson Group (DRUG) discloses 1.28M shares, 13.1% stake - Stock Titan
Bright Minds Biosciences Inc. (DRUG) Eps Diluted (TTM) - Zacks Investment Research
Vivo entities disclose 504,645 shares in Bright Minds Biosciences (DRUG) - Stock Titan
TradingKey - TradingKey
Bright Minds Biosciences Inc expected to post a loss of C$1.19 a shareEarnings Preview - TradingView
Bright Minds Biosciences (DRUG) to Release Earnings on Friday - MarketBeat
Trading Systems Reacting to (DRUG) Volatility - Stock Traders Daily
This Insider Has Just Sold Shares In Bright Minds Biosciences - simplywall.st
DRUG SEC FilingsBright Minds Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Cormorant sells $9.78m in Bright Minds Biosciences stock - Investing.com UK
Cormorant sells $9.78m in Bright Minds Biosciences stock By Investing.com - Investing.com Australia
[SCHEDULE 13G/A] BRIGHT MINDS BIOSCIENCES INC. Amended Passive Investment Disclosure - Stock Titan
Insider Selling: Bright Minds Biosciences (NASDAQ:DRUG) Major Shareholder Sells 109,331 Shares of Stock - MarketBeat
Bright Minds Biosciences(DRUG.US) Insider Sells US$9.79 Million in Common Stock - Moomoo
Bright Minds Biosciences (DRUG) holder sells 109,331 shares in open market - Stock Titan
Bright Minds announces ATM offering up to $100 million - MSN
How Bright Minds Biosciences Inc. (DRUG) Affects Rotational Strategy Timing - Stock Traders Daily
Bright Minds (DRUG) Year-Ahead Outlook | Q4 2025: Earnings ReportSurprise Score - Cổng thông tin điện tử tỉnh Tây Ninh
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Top 3 Canadian Biotech Stocks in 2026 - Investing News Network
Bright Minds Biosciences (NASDAQ:DRUG) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Shroom stocks rise as Trump is said to sign executive order on psychedelic drug - Seeking Alpha
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Sees Significant Growth in Short Interest - MarketBeat
(DRUG) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Bright Minds Biosciences (NASDAQ:DRUG) Earns Buy Rating from Analysts at Jefferies Financial Group - MarketBeat
Jefferies initiates Bright Minds stock with buy on epilepsy drug By Investing.com - Investing.com South Africa
Jefferies initiates Bright Minds stock with buy on epilepsy drug - Investing.com
Total debt per share of Bright Minds Biosciences Inc. – NEO:DRUG - TradingView
Certain RSUs of Bright Minds Biosciences Inc. are subject to a Lock-Up Agreement Ending on 8-APR-2026. - marketscreener.com
Certain Options of Bright Minds Biosciences Inc. are subject to a Lock-Up Agreement Ending on 8-APR-2026. - marketscreener.com
Bright Minds Biosciences Inc (DRUG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.25%
0.46%
자본화:
|
볼륨(24시간):